Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A SAFETY RUN-IN AND PHASE 2, OPEN-LABEL, MULTICENTRE, STUDY INVESTIGATING SAFETY, TOLERABILITY AND EFFECTIVENESS OF VENETOCLAX ADD IN COMBINATION AT FLUDARABINE, CYRATABINE AND IDARUBICINE IN INDUCTION THERAPY OF NEW ONSET NON-M3 ACUTE MYELOID LEUKEMIA. V-FIRST - AML1718
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available4 trial-level findings · Read insights
- Between December 2018 and December 2022, 124 patients were enrolled across 17 national centers.
- Of 133 screened patients, seven failed screening because of unmet inclusion criteria (n=5) or physician decision related to FLT3 positivity (n=2).
- Two patients initially considered eligible were subsequently excluded after favorable-risk cytogenetic or molecular findings were confirmed.
- All 124 enrolled patients received the planned first induction treatment, which was administered during hospitalization.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietic Stem Cell Transplantation. ALL2418
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-Label, multicentre, study investigating tolerability and efficacy of Gilteritinib in combination with fludarabine, cytarabine and idarubicin (FLAI) as induction therapy of newly diagnosed non-M3 FLT3-positive acute myeloid leukemia.GIMEMA AML2924
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST?
The 2026-10-09 snapshot links Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST to 5 distinct CTIS trials. Recorded services include Laboratory services, Central Medical Reading or Imaging Reading. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST conducted?
The linked trials record locations in 18 countries, including Italy, Austria, Bulgaria, Czechia, Germany. These are trial locations, not confirmed office locations or countries where Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST delivered services.
What can this page tell me about Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.